ALB and neoplasm: These studies have shown that the combination of HSA and RSV, on the one hand, slowed down the release of the drug at the injection site, and on the other hand, significantly increased the RSV accumulation in the tumor regarding RSV-loaded HSA nanoparticles without folic acid as a targeting agent.